We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Sphere Medical

Sphere Medical develops medical monitoring and diagnostic equipment, including the CE-marked Proxima platform for mea... read more Featured Products: More products

Download Mobile App




Blood Gas Analyzer Supports Rapid Critical Point-of-Care Measurements

By LabMedica International staff writers
Posted on 02 Oct 2014
Print article
Sphere Medical\'s Proxima in-line patient-dedicated arterial blood gas analyzer
The Proxima in-line patient-dedicated arterial blood gas analyzer (Photo courtesy of Sphere Medical)
A novel miniature, patient dedicated in-line blood gas analyzer improves critical care by providing near real-time measurements at laboratory analyzer accuracy.

Sphere Medical (Cambridge, UK), innovator in critical care monitoring and diagnostics equipment, has launched its cutting-edge analyzer, Proxima, at the Association of Anesthetists of Great Britain and Ireland Annual Congress (AAGBI) 2014 (September 17-19, 2014, Harrogate, UK). The Proxima miniaturized blood gas analyzer uniquely delivers rapid, frequent results at patient bedside to enable fast response, proactive critical care—closer control of therapeutic response leading to improved patient outcome, as well as to reduced overall cost of care.

CE-marked and designed for critical care environments, the Proxima System incorporates a dedicated bedside monitor and the Proxima Sensor integrated into a patient’s arterial line. This enables blood to be measured directly at point-of-care without need to leave the patient or manipulate samples and cartridges, which can add to the workload of frontline care staff. Measured to laboratory analyzer accuracy, results are rapidly displayed on the bedside monitor and can be electronically transferred for permanent record.

Simple to use, Proxima enables closed blood sampling and is operated via the touch screen interface of its bedside monitor. When a blood gas analysis is required, blood is withdrawn from the patient directly into the Proxima Sensor without need to open the line, take a sample, and walk away for analysis. Once analysis is completed, all blood is returned to the patient, thereby ensuring blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. A Proxima Sensor is a disposable transducer which can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required. The system also carries out all quality control checks that would be undertaken on a traditional blood gas analyzer to ensure validity of test results. It also includes a facility to be challenged with liquid controls.

Dr. Tom Clutton-Brock, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” “Frequent measurement of arterial blood samples is a key component in the effective management of patients in the critical care environment, particularly those that are unstable,” said Dr. Wolfgang Rencken, CEO of Sphere Medical, “we have developed and launched Proxima to keep the caregiver by the patient, conserve blood, and rapidly return blood gas results to aid early decision making and closer control of therapy for critically ill patients—all of which will ultimately improve patient outcomes.”

Also at AAGBI 2014, Sphere Medical sponsored an industry seminar where Dr. Clutton-Brock presented on “True Point-of-Care Testing,” discussing challenges of maintaining control of patient physiology in the ITU, focusing on the frequency of arterial blood sample testing ideally required, and associated limitations such as staff time involved, costs, and blood conservation. He also considered how matters might change if these limitations were removed.

Related Links:
Sphere Medical

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
TORCH Infections Test
TORCH Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.